Rinvoq vs Skyrizi
Side-by-side cost comparison based on Medicare Part D data
Rinvoq
Upadacitinib
Manufactured by AbbVie
Skyrizi
Risankizumab
Manufactured by AbbVie
Rinvoq costs 22% less per claim than Skyrizi ($3,498.00 vs $4,475.00).
Cost Per Claim
Medicare Spending
Beneficiaries
Annual Cost Per Patient
Full Comparison
| Metric | Rinvoq | Skyrizi |
|---|---|---|
| Avg Cost Per Claim | $3,498.00 | $4,475.00 |
| Total Medicare Spending | $2.3B | $2.3B |
| Total Beneficiaries | 92,000 | 78,000 |
| Total Claims | 648,000 | 524,000 |
| Annual Cost/Patient | $24,641.00 | $30,064.00 |
| Year-over-Year Change | +56.3% | +42.8% |
| Generic Available | No | No |
| Patent Expiration | Aug 16, 2033 | Apr 23, 2035 |
| Manufacturer | AbbVie | AbbVie |
| Condition | Autoimmune Diseases | Autoimmune Diseases |
| Generic Name | Upadacitinib | Risankizumab |
Rinvoq vs Skyrizi: What the Data Shows
Rinvoq (Upadacitinib) and Skyrizi (Risankizumab) are both used to treat autoimmune diseases. Based on Medicare Part D data, Rinvoq costs $3,498.00 per claim, which is 22% less than Skyrizi at $4,475.00 per claim.
Medicare spent $2.3B on Rinvoq and $2.3B on Skyrizi. In terms of patient reach, Rinvoq serves more beneficiaries (92,000 vs 78,000).
Year-over-year spending changed +56.3% for Rinvoq and +42.8% for Skyrizi. Rinvoq saw significant spending growth, suggesting increased utilization or price increases. Skyrizi saw significant spending growth, suggesting increased utilization or price increases.
Neither drug currently has a generic version. Rinvoq patent expires Aug 16, 2033. Skyrizi patent expires Apr 23, 2035.
Frequently Asked Questions
Rinvoq is cheaper at $3,498.00 per claim, compared to $4,475.00 for Skyrizi. That makes Rinvoq about 22% less expensive per claim based on Medicare Part D data.
Yes, both Rinvoq and Skyrizi are used to treat autoimmune diseases. Your doctor can help determine which medication is more appropriate for your specific situation.
Neither drug currently has a generic version available. Rinvoq patent expires Aug 16, 2033. Skyrizi patent expires Apr 23, 2035.
Medicare Part D spent $2.3B on Rinvoq covering 92,000 beneficiaries, and $2.3B on Skyrizi covering 78,000 beneficiaries.
Explore Further
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.